# US Esophageal Squamous Cell Carcinoma Market > US Esophageal Squamous Cell Carcinoma Market Research Report By End User (Hospital, Specialty Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.16% - **2024:** $ 283.9 Million - **2025:** $ 307.07 Million - **2035:** $ 673 Million - **Key Players:** Roche (CH), Bristol-Myers Squibb (US), Merck & Co (US), AstraZeneca (GB), Novartis (CH), Eli Lilly and Company (US), Amgen (US), Pfizer (US), Bayer (DE) **Report ID:** MRFR/LS/15213-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-esophageal-squamous-cell-carcinoma-market-16741 --- ## Market Summary ## **US Esophageal Squamous Cell Carcinoma Market Overview** As per MRFR analysis, the US Esophageal Squamous Cell Carcinoma Market Size was estimated at 240.27 (USD Million) in 2023. The US Esophageal Squamous Cell Carcinoma Market Industry is expected to grow from 270 (USD Million) in 2024 to 650 (USD Million) by 2035. The US Esophageal Squamous Cell Carcinoma Market CAGR (growth rate) is expected to be around 8.314% during the forecast period (2025 - 2035). ### **Key US Esophageal Squamous Cell Carcinoma Market Trends Highlighted** In the US Esophageal Squamous Cell Carcinoma market, key market drivers include an increasing awareness of the disease alongside rising rates of risk factors such as tobacco and alcohol consumption. Efforts by health organizations to promote early detection and prevention are prompting more individuals to seek medical consultations, which significantly boosts the demand for innovative treatment options. The growing adoption of personalized medicine is transforming the way healthcare professionals approach the treatment of esophageal cancers, allowing for tailored therapies that align more closely with individual patient profiles. This trend not only enhances patient outcomes but also spurs ongoing research and development in targeted therapies. Recent trends show a surge in clinical trials focused on novel therapeutic agents, highlighting a commitment to advancing treatment methodologies within the US. The National Cancer Institute reports a steady increase in the number of ongoing studies aimed at developing new drug options and combination therapies which aim to improve survival rates and quality of life for patients diagnosed with Esophageal Squamous Cell Carcinoma. Opportunities within the US market can also be found in the integration of advanced technologies such as artificial intelligence and machine learning in diagnostics and treatment planning. Moreover, the rise in collaborative efforts between academic institutions, biotech companies, and pharmaceutical organizations presents avenues for innovation and growth in therapy options. Such partnerships are instrumental in expediting the development of effective treatments while addressing the unique challenges posed by this disease in the US population. This integrated approach positions the market for future advancements, optimizing patient care and potentially increasing the accessibility of novel therapies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Esophageal Squamous Cell Carcinoma Market Drivers** ### **Increasing Incidence of Esophageal Cancer** The US has witnessed a concerning rise in the incidence of esophageal cancer, particularly Esophageal Squamous Cell Carcinoma. According to the American Cancer Society, the estimated number of new esophageal cancer cases in the US in 2023 was around 20,640, with the numbers expected to escalate further due to factors such as increasing tobacco use and dietary influences. The rising prevalence of risk factors aids in driving the US Esophageal Squamous Cell Carcinoma Market Industry as more patients enter the healthcare system requiring innovative treatment options. Moreover, organizations, such as the National Cancer Institute, are focusing on expanding awareness and research initiatives aimed at tackling this increase, which further solidifies the urgent need for market growth and product development to cater to the rising number of patients. ### **Advancements in Treatment Modalities** Rapid advancements in treatment modalities for Esophageal Squamous Cell Carcinoma significantly contribute to market growth. The introduction of targeted therapies and immunotherapy has shown promising results. According to the National Comprehensive Cancer Network, advancements such as the use of immune checkpoint inhibitors have improved the survival rate of patients affected by this type of cancer. This progress opens new paths for therapies that can specifically target cancer cells effectively while preserving healthy cells. Major pharmaceutical companies are increasingly investing in Research and Development to develop innovative therapies, which creates a robust market for such products in the US Esophageal Squamous Cell Carcinoma Market Industry. ### **Government Initiatives and Funding** Government initiatives aimed at increasing funding for cancer research play a crucial role in the expansion of the US Esophageal Squamous Cell Carcinoma Market Industry. The National Institutes of Health (NIH) has allocated billions to cancer research with a notable emphasis on esophageal cancer, facilitating new research projects, clinical trials, and treatment developments. In its 2022 budget, the NIH announced approximately $50 billion in funding, underscoring its commitment to tackling cancer and benefiting treatment modalities. This substantial investment promotes the continuous growth of the market by encouraging innovations and fostering a collaborative environment among researchers, healthcare professionals, and pharmaceutical developers. ## **US Esophageal Squamous Cell Carcinoma Market Segment Insights** ### **Esophageal Squamous Cell Carcinoma Market End User Insights** The US **[Esophageal Squamous Cell Carcinoma Market](../../../reports/esophageal-squamous-cell-carcinoma-market-12048)** showcases significant diversity in its End User segment, comprising hospitals, specialty centers, and other healthcare institutions. Hospitals hold a prominent role in the treatment of esophageal squamous cell carcinoma due to their advanced facilities, comprehensive care, and multidisciplinary teams capable of addressing varied patient needs. These institutions typically provide extensive resources for both diagnosis and treatment, ensuring patients receive critical care, including surgery, chemotherapy, and radiation therapy. Specialty centers have emerged as essential players as well, focusing on specific types of cancers and offering specialized services that cater to esophageal cancer patients. These centers often feature cutting-edge technologies and access to clinical trials, contributing to improved treatment outcomes and patient experiences. The growing emphasis on personalized medicine is poised to drive demand for these specialized facilities, enabling tailored treatment options that address the unique characteristics of each patient's cancer. Additionally, the 'Others' category comprises outpatient clinics and physician offices, which serve as important supplemental care providers. These establishments offer supportive services and follow-up care, enhancing patient accessibility to treatment. The market growth is fueled by an increasing incidence of esophageal cancer, heightened awareness regarding cancer screening, and advancements in healthcare technology. As healthcare delivery continues to evolve, the importance of each End User in the overall treatment landscape becomes increasingly evident, reflecting a shift toward more integrated approaches to cancer care in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Esophageal Squamous Cell Carcinoma Market Key Players and Competitive Insights** The US Esophageal Squamous Cell Carcinoma Market is characterized by a competitive landscape driven by advancements in cancer therapeutics and increasing R&D initiatives aimed at novel treatment modalities. The rising incidence of esophageal cancer, particularly esophageal squamous cell carcinoma, has spurred the need for innovative therapies and significant investment from key players in the pharmaceutical sector. The market is shaped by a combination of established companies and emerging startups that focus on developing targeted therapies, immunotherapies, and chemotherapy agents. Stakeholders in this space prioritize strategic collaborations and partnerships to accelerate drug development processes, enhance distribution channels, and improve patient outcomes in the fight against this aggressive form of cancer. In the US market specifically, Genentech stands out as a leading player known for its dedication to innovative cancer treatments. The company’s strong presence in the oncology space is bolstered by a robust pipeline of targeted therapies aimed at esophageal squamous cell carcinoma, leveraging its advanced research capabilities and expertise in molecular biology. Genentech’s commitment to developing personalized medicine solutions is reflected in its focus on biomarker-driven therapies, which allow for tailored treatment approaches that enhance efficacy and minimize side effects. The organization has established strategic alliances with academic institutions and research centers to further its understanding of this disease and improve patient care in the US. Its strong brand reputation and comprehensive patient support programs contribute to Genentech's solid foothold in the US Esophageal Squamous Cell Carcinoma Market, making it a symbol of innovation and patient-centric care. Bristol Myers Squibb is another significant entity within the US Esophageal Squamous Cell Carcinoma Market, recognized for its comprehensive portfolio of oncology products and its keen focus on the development of novel therapeutic agents. The company effectively leverages its extensive expertise in immuno-oncology, with a range of key products that address various cancer types, including esophageal cancer. Bristol Myers Squibb has pursued strategic mergers and acquisitions to expand its capabilities and enhance its therapeutic offerings, solidifying its market presence. This has allowed the company to maintain a competitive edge through innovative treatments that target specific cancer pathways and modalities. Their commitment to research and development is evident in their investments in clinical trials and studies, designed to evaluate the efficacy and safety of their products in treating esophageal squamous cell carcinoma. The strong market position of Bristol Myers Squibb is supported by its established relationships with healthcare providers, marketing strategies that emphasize education and awareness, and ongoing efforts to improve access to their therapies for patients across the United States. ### **Key Companies in the US Esophageal Squamous Cell Carcinoma Market Include** ## **US Esophageal Squamous Cell Carcinoma Market Industry Developments** The US Esophageal Squamous Cell Carcinoma Market has seen significant developments recently, reflecting advancements in treatments and regulatory updates. For instance, in September 2023, Bristol Myers Squibb announced promising clinical trial results for its innovative immunotherapy that targets metastatic esophageal cancer, enhancing treatment options for patients. Additionally, Merck reported success with its combination therapy, which received accelerated approval from the FDA earlier this year, marking an important milestone. Meanwhile, Genentech is actively working on next-generation sequencing technologies to personalize treatment for patients, with partnerships being forged with various research institutions across the country. In terms of market dynamics, as of October 2023, AstraZeneca noted a 12% growth in sales attributed to its recent lung cancer therapies that may have overlap with esophageal treatment protocols, underlining the importance of cross-industry innovation. While no recent mergers or acquisitions have been publicly reported in this specific market segment for the relevant companies, continued investments in Research and Development activities by major players like Novartis and Pfizer are expected to drive forward the market growth and improve patient outcomes for Esophageal Squamous Cell Carcinoma. ## **US Esophageal Squamous Cell Carcinoma Market Segmentation Insights** ### **Esophageal Squamous Cell Carcinoma Market End User Outlook** ## Market Drivers ### Rising Incidence Rates The esophageal squamous-cell-carcinoma market is experiencing growth due to the increasing incidence rates of this cancer type in the US. Recent statistics indicate that esophageal cancer cases have risen by approximately 2.5% annually over the past decade. This trend is attributed to various factors, including lifestyle changes and dietary habits. As more individuals are diagnosed, the demand for effective treatment options and diagnostic tools intensifies, thereby driving market expansion. The healthcare system is responding to this surge by investing in research and development, which is likely to enhance the availability of innovative therapies. Consequently, the rising incidence rates are a crucial driver for the esophageal squamous-cell-carcinoma market, prompting stakeholders to focus on developing targeted interventions. ### Increasing Awareness and Education The esophageal squamous-cell-carcinoma market is benefiting from heightened awareness and education initiatives aimed at both healthcare professionals and the general public. Campaigns focused on risk factors, symptoms, and the importance of early detection are gaining traction. This increased awareness is likely to lead to earlier diagnoses, which can significantly improve treatment outcomes. Organizations dedicated to cancer research and patient advocacy are actively promoting educational resources, contributing to a more informed patient population. As awareness grows, the demand for screening and treatment options in the esophageal squamous-cell-carcinoma market is expected to rise, further driving market growth. ### Advancements in Diagnostic Technologies Technological advancements in diagnostic tools are significantly impacting the esophageal squamous-cell-carcinoma market. Innovations such as endoscopic ultrasound and advanced imaging techniques have improved early detection rates, which is vital for effective treatment. Enhanced diagnostic capabilities allow for more accurate staging and characterization of tumors, leading to better patient outcomes. The market for diagnostic devices is projected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 5% over the next few years. As healthcare providers increasingly adopt these technologies, the esophageal squamous-cell-carcinoma market is likely to benefit from improved patient management and treatment planning, ultimately enhancing survival rates. ### Regulatory Support for Innovative Therapies Regulatory support for innovative therapies is emerging as a key driver in the esophageal squamous-cell-carcinoma market. The US Food and Drug Administration (FDA) has implemented expedited review processes for breakthrough therapies, which encourages pharmaceutical companies to develop new treatment options. This regulatory environment fosters innovation and allows for faster access to potentially life-saving therapies for patients. As a result, the esophageal squamous-cell-carcinoma market is likely to see an influx of new drugs and treatment strategies, enhancing the overall therapeutic landscape. The supportive regulatory framework is crucial for driving advancements in treatment and improving patient outcomes. ### Growing Investment in Research and Development Investment in research and development (R&D) is a significant driver for the esophageal squamous-cell-carcinoma market. Pharmaceutical companies and research institutions are allocating substantial resources to discover novel therapies and improve existing treatment modalities. The US government has also increased funding for cancer research, with allocations reaching over $6 billion annually. This financial commitment fosters innovation and accelerates the development of new drugs and treatment protocols. As a result, the esophageal squamous-cell-carcinoma market is poised for growth, as new therapies enter the market and provide patients with more effective options. The focus on R&D is likely to enhance the overall landscape of cancer treatment. ## Future Outlook The [Esophageal Squamous Cell Carcinoma Market](https://www.marketresearchfuture.com/reports/esophageal-squamous-cell-carcinoma-market-12048) is projected to grow at an 8.16% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing awareness. **New opportunities:** - Development of targeted immunotherapy treatments for enhanced patient outcomes. - Expansion of telehealth services for remote patient monitoring and consultations. - Investment in AI-driven diagnostic tools to improve early detection rates. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Diagnosis: Endoscopy (Largest) vs. CT Scan (Fastest-Growing) In the US esophageal squamous-cell-carcinoma market, the diagnosis segment is primarily dominated by endoscopy, which holds the largest market share. Endoscopy's ability to provide direct visualization and tissue sampling makes it a preferred diagnostic tool among healthcare professionals. Meanwhile, CT scans are gaining traction due to advancements in imaging technology and their increasingly crucial role in treatment planning and staging of the disease. This dual dominance illustrates the variety of diagnostic modalities available to clinicians. Growth trends in the diagnosis segment are driven by factors such as increasing awareness of esophageal cancer screening and the rise in high-risk populations. Technological innovations enhance the capabilities of both endoscopy and CT scans, enabling earlier detection and better treatment outcomes. The push for personalized medicine also propels market growth, with tailored diagnostic approaches becoming more commonplace, further solidifying the significance of these diagnostic methods in clinical practice. Endoscopy (Dominant) vs. CT Scan (Emerging) Endoscopy remains the dominant diagnostic tool in the esophageal squamous-cell-carcinoma segment, celebrated for its precision and effectiveness. This method allows direct visualization of the esophagus, facilitating thorough examinations and enabling biopsies that are essential for accurate diagnosis. As the dominant player, endoscopy has established a strong foothold in clinical protocols due to its proven track record. Conversely, CT scans are emerging as a vital imaging modality, particularly in staging and therapeutic planning. Their role has evolved with technological advancements, offering enhanced resolution and faster processing times, making them a compelling option for clinicians seeking comprehensive insights into cancer progression. This growing acceptance reflects the dynamic nature of diagnostic approaches in oncology. ### By Treatment: Surgery (Largest) vs. Immunotherapy (Fastest-Growing) In the US esophageal squamous-cell-carcinoma market, surgery accounts for the largest share, driven by its necessity in advanced cases where tumor removal is vital for patient prognosis. Following surgery, chemotherapy and radiotherapy play significant roles in treatment regimens, providing essential post-surgical support. Immunotherapy, while presently a smaller segment, demonstrates substantial potential as it gains acceptance and is included in treatment protocols, gradually increasing its market presence. Growth trends in this segment are influenced by factors such as evolving clinical guidelines and a rising understanding of personalized medicine. The increasing frequency of diagnoses is boosting demand for robust treatment options, including the newer immunotherapy approaches. Furthermore, research and development efforts focusing on targeted therapies are paving the way for innovative solutions, with immunotherapy leading as the forefront of emerging treatments. Surgery (Dominant) vs. Immunotherapy (Emerging) Surgery remains the dominant treatment modality in the US esophageal squamous-cell-carcinoma market, known for its effectiveness in offering the best chance for long-term survival in patients with localized tumors. As the primary choice, it is often paired with adjuvant therapies like chemotherapy and radiotherapy. In contrast, immunotherapy is emerging as a transformative treatment avenue, targeting specific cancer cell mechanisms to elicit a stronger immune response. This innovative treatment approach is gaining momentum due to successful clinical trials and its ability to improve patient outcomes with fewer side effects compared to traditional treatments, making it a promising alternative for those who do not respond well to conventional therapies. ### By End User: Hospitals (Largest) vs. Specialty Centres (Fastest-Growing) In the US esophageal squamous-cell-carcinoma market, hospitals hold a significant share, dominating the landscape due to their comprehensive healthcare services and advanced treatment options. This established infrastructure allows them to cater to a larger patient base, making them the go-to choice for many patients requiring esophageal cancer treatment. On the other hand, specialty centres, while smaller in market share, are gaining traction as they focus on targeted therapies and personalized medicine. This shift in preference is reflective of the evolving treatment landscape. Growth trends indicate that specialty centres are emerging as the fastest-growing segment due to increasing demand for specialized care and advancements in treatment options tailored to esophageal squamous-cell carcinoma. The focus on precision medicine and the establishment of multidisciplinary teams in these centres enhance treatment outcomes. Furthermore, rising awareness regarding the disease and its management drives patients towards seeking specialized care, contributing to the robust growth of this segment. Hospitals (Dominant) vs. Specialty Centres (Emerging) Hospitals play a dominant role in the treatment of esophageal squamous-cell carcinoma, offering a wide range of services, including surgery, chemotherapy, and radiation therapy, backed by robust infrastructure and resources. Their ability to provide comprehensive care attracts a larger patient population. Conversely, specialty centres are emerging as key players in this market, focusing on innovative treatment modalities and specialized care. These centres often employ advanced technologies and expertise in esophageal cancer, catering to the growing patient demand for personalized and effective treatment options. The competitive differentiation is significant, as hospitals leverage their extensive networks while specialty centres capitalize on their specialized knowledge and quicker adoption of new therapies. ## Competitive Benchmarking The esophageal squamous-cell-carcinoma market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on personalized medicine. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Merck & Co (US) are actively engaged in developing novel therapies and expanding their market presence. Roche (CH) has positioned itself as a leader in targeted therapies, emphasizing the importance of biomarker-driven treatment approaches. Meanwhile, Bristol-Myers Squibb (US) is leveraging its expertise in immunotherapy to enhance treatment options for patients, while Merck & Co (US) focuses on integrating advanced technologies into its research and development processes. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and patient-centric approaches are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the esophageal squamous-cell-carcinoma market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, although it also necessitates strategic collaborations to maintain competitive advantage. In October Roche (CH) announced a collaboration with a leading biotechnology firm to develop a novel combination therapy targeting esophageal squamous-cell-carcinoma. This strategic move is significant as it not only enhances Roche's portfolio but also underscores the growing trend of partnerships aimed at accelerating drug development timelines. Such collaborations may lead to more effective treatment regimens, thereby improving patient outcomes. In September Bristol-Myers Squibb (US) received FDA approval for a new immunotherapy regimen specifically designed for esophageal squamous-cell-carcinoma. This approval is pivotal, as it expands the company's therapeutic offerings and reinforces its commitment to addressing unmet medical needs in this area. The introduction of this regimen is likely to enhance patient access to cutting-edge treatments, positioning Bristol-Myers Squibb as a formidable competitor in the market. In August Merck & Co (US) launched a digital health initiative aimed at improving patient engagement and adherence to treatment protocols for esophageal squamous-cell-carcinoma. This initiative reflects a broader trend towards digitalization in healthcare, where technology is utilized to enhance patient outcomes. By integrating digital tools into its treatment strategies, Merck & Co is likely to strengthen its market position and foster long-term relationships with patients and healthcare providers. As of November current competitive trends indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development processes. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a greater emphasis on technological advancements and supply chain reliability, rather than solely on price. This shift suggests that companies that prioritize innovation and patient-centric solutions will likely emerge as leaders in the esophageal squamous-cell-carcinoma market. ## Recent News & Developments The US Esophageal Squamous Cell Carcinoma Market has seen significant developments recently, reflecting advancements in treatments and regulatory updates. For instance, in September 2023, Bristol Myers Squibb announced promising clinical trial results for its innovative immunotherapy that targets metastatic esophageal cancer, enhancing treatment options for patients. Additionally, Merck reported success with its combination therapy, which received accelerated approval from the FDA earlier this year, marking an important milestone. Meanwhile, Genentech is actively working on next-generation sequencing technologies to personalize treatment for patients, with partnerships being forged with various research institutions across the country. In terms of market dynamics, as of October 2023, AstraZeneca noted a 12% growth in sales attributed to its recent lung cancer therapies that may have overlap with esophageal treatment protocols, underlining the importance of cross-industry innovation. While no recent mergers or acquisitions have been publicly reported in this specific market segment for the relevant companies, continued investments in Research and Development activities by major players like Novartis and Pfizer are expected to drive forward the market growth and improve patient outcomes for Esophageal Squamous Cell Carcinoma. ## Report Scope | MARKET SIZE 2024 | 283.9(USD Million) | | --- | --- | | MARKET SIZE 2025 | 307.07(USD Million) | | MARKET SIZE 2035 | 673.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.16% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche (CH), Bristol-Myers Squibb (US), Merck & Co (US), AstraZeneca (GB), Novartis (CH), Eli Lilly and Company (US), Amgen (US), Pfizer (US), Bayer (DE) | | Segments Covered | Diagnosis, Treatment, End User | | Key Market Opportunities | Advancements in targeted therapies and immunotherapies enhance treatment options in the esophageal squamous-cell-carcinoma market. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the esophageal squamous-cell-carcinoma market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation for the US esophageal squamous-cell-carcinoma market in 2024?** A: The overall market valuation was $283.9 Million in 2024. **Q: What is the projected market valuation for the US esophageal squamous-cell-carcinoma market by 2035?** A: The projected market valuation for 2035 is $673.0 Million. **Q: What is the expected CAGR for the US esophageal squamous-cell-carcinoma market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 8.16%. **Q: Which companies are considered key players in the US esophageal squamous-cell-carcinoma market?** A: Key players include Roche (CH), Bristol-Myers Squibb (US), Merck & Co (US), and others. **Q: What were the revenue ranges for the Endoscopy segment in the US esophageal squamous-cell-carcinoma market?** A: The revenue range for the Endoscopy segment was $56.78 Million to $134.0 Million. **Q: How much revenue did the Chemotherapy segment generate in the US esophageal squamous-cell-carcinoma market?** A: The Chemotherapy segment generated revenue between $80.0 Million and $200.0 Million. **Q: What is the revenue range for the Surgery segment in the US esophageal squamous-cell-carcinoma market?** A: The revenue range for the Surgery segment was $50.0 Million to $120.0 Million. **Q: What are the projected revenue figures for the Hospitals end user segment by 2035?** A: The projected revenue for the Hospitals end user segment is expected to reach between $113.56 Million and $270.0 Million. **Q: What revenue did the Immunotherapy segment achieve in the US esophageal squamous-cell-carcinoma market?** A: The Immunotherapy segment achieved revenue between $60.0 Million and $150.0 Million. **Q: What was the revenue range for the Others segment in the Diagnosis category?** A: The revenue range for the Others segment in the Diagnosis category was $127.12 Million to $304.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-esophageal-squamous-cell-carcinoma-market-16741*